Abstract

Vericel will release its second-quarter 2026 results on July 30, 2026 Pre-Market; this preview summarizes consensus expectations for revenue, margin, net income, and adjusted EPS alongside institutional perspectives and business drivers.

Market Forecast

Market expectations for the current quarter point to revenue of 72.69 million US dollars, adjusted EPS of -0.03, and EBIT of -2.82 million US dollars, with year-over-year changes of 12.72%, 9.98%, and -83.34%, respectively. Consensus implies relatively resilient gross profitability consistent with the prior quarter’s 72.00% gross margin, with net losses expected to narrow sequentially; the net margin is anticipated to improve year over year based on scale from cartilage repair products and steady Epicel demand. The main business is projected to continue mid-teens growth, supported by demand for the third-generation autologous chondrocyte implantation franchise and stable burn-care volumes. The cartilage repair portfolio remains the most promising segment, with an estimated quarterly revenue contribution of 56.40 million US dollars last quarter and double-digit year-over-year growth.

Last Quarter Review

In the prior quarter, Vericel reported revenue of 68.43 million US dollars, a gross margin of 72.00%, a GAAP net loss attributable to shareholders of 6.30 million US dollars with a net margin of -9.21%, and adjusted EPS of -0.12, with year-over-year growth of 30.09% for revenue and 47.83% for adjusted EPS. Commercial traction was strong in cartilage repair, helping the company exceed revenue expectations while operating loss narrowed versus estimates, and demand remained resilient across burn-care products. Main business highlights included the third-generation autologous chondrocyte implantation products delivering 56.40 million US dollars, Epicel contributing 10.89 million US dollars, and Nexobrid adding 1.14 million US dollars, reflecting a diversified growth base and healthy procedural trends.

Current Quarter Outlook

Cartilage Repair Franchise

Demand for the third-generation autologous chondrocyte implantation products is expected to remain the primary revenue driver this quarter. The setup features healthy procedure volumes supported by improving surgeon productivity and steady referral pipelines, which historically peak into summer months. With high gross margin characteristics and leverage on fixed manufacturing costs, the franchise provides the clearest line of sight to sustaining a gross margin profile similar to the prior quarter’s 72.00%. Key variables to watch include scheduling dynamics at surgical centers, payer authorization timelines, and case mix across knee indications, which can influence realized pricing and throughput. The market will also monitor the cadence of new surgeon onboarding and regional adoption curves, which influence quarterly variability but trend favorably over a multi-quarter horizon.

Burn and Wound Care

Epicel and Nexobrid form the complementary burn-and-wound portfolio and are expected to deliver steady contributions. Epicel demand tends to be episodic due to the nature of severe burn cases, but pipeline visibility and hospital readiness suggest stable to modestly higher utilization into the quarter. Nexobrid remains a smaller contributor, though additional hospital formulary access and clinician familiarity can expand usage; the near-term focus is execution within existing accounts. From a profitability perspective, the burn portfolio is less accretive than cartilage repair but supports operating leverage by spreading fixed costs and broadening the company’s revenue base. Any incremental uptake in burn indications, emergency stockpiles, or regional trauma activity could add upside, albeit with inherent variability.

Key Stock Drivers This Quarter

Investors are likely to focus on three areas: revenue conversion from the cartilage repair pipeline, trajectory of operating expenses versus revenue growth, and margin commentary. Delivering the 12.72% year-over-year revenue growth while holding gross margin near the prior quarter’s 72.00% would reinforce a path toward improved operating leverage. Commentary on sequential net loss and adjusted EPS will also be important, as consensus expects adjusted EPS of approximately -0.03 and EBIT of -2.82 million US dollars, implying incremental efficiency gains. Management’s color on procedure seasonality, payer dynamics, and production yields could sway sentiment, as could any updates on channel inventory or hospital purchasing patterns in burn care.

Analyst Opinions

Analyst commentary collected in recent months skews constructive, emphasizing durable mid-teens top-line growth led by cartilage repair, healthy gross margins, and a pathway to narrowing losses. Bullish opinions outnumber cautious views based on the balance of recent previews, citing the company’s consistent execution in its core franchise and upside optionality from burn-care stabilization. Well-followed firms highlight that the revenue mix tilt toward higher-margin cartilage repair supports attractive unit economics and improving operating leverage as volumes scale, which aligns with consensus for adjusted EPS improvement and a smaller operating loss this quarter. The majority view anticipates a clean quarter with in-line to modestly above-consensus revenue, stable gross margin relative to the prior quarter, and balanced Opex control sufficient to sustain the trajectory toward profitability.